ALLMedicine™ Leptomeningeal Carcinomatosis Center

Mar 3rd, 2022 - INTERVENTION: Enrolled patients will receive stereotactic radiosurgery (SRS) to all metastases followed by surgical resection of resectable metastases within one to 10 days following SRS. Pathologic specimens will be analyzed, and the patient will...

Jan 30th, 2022 - Central nervous system (CNS) metastases are a prominent cause of morbidity and mortality in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC). The phase 2 ASCEND-7 (NCT02336451) study was specifically designed to assess the effi...

Nov 14th, 2021 - Physician assistants (PAs) and NPs are essential to quality care delivery. The need to demonstrate value and optimize PA and NP roles in neurology subspecialty clinics is unmet. We outline the development of a PA- and NP-led neuro-oncology procedu...

Oct 14th, 2021 - Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab unt...

Aug 1st, 2021 - Cauda equina syndrome (CES) is a challenging condition and it can be caused by variable entities. Leptomeningeal carcinomatosis (LC) is a multifocal seeding of the leptomeninges by malignant cells and it is observed in 1-8% of patients with solid ...

Mar 3rd, 2022 - INTERVENTION: Enrolled patients will receive stereotactic radiosurgery (SRS) to all metastases followed by surgical resection of resectable metastases within one to 10 days following SRS. Pathologic specimens will be analyzed, and the patient will...

Jan 26th, 2021 - This is an open-label phase II study of pembrolizumab in patients with advanced solid tumors with leptomeningeal carcinomatosis (LMD). Patients may have received any number of prior therapies for their respective solid tumors, but must not have re...

Jun 7th, 2016 - This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1...

Jan 31st, 2022 - Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier (BBB), a highly restrictive interface between the bloodstream and the brain that prevents most dru...

Apr 2nd, 2021 - Transcript: Sarah A. Hurvitz, MD: HER2-positive breast cancer is a unique subtype. Generally the way we look at breast cancer as a whole is, we generally group them based on expression of receptors. There is hormone receptor-positive breast ca...

Apr 2nd, 2021 - Transcript: Sai-Hong Ignatius Ou, MD, PhD: In summary, the approval of osimertinib as frontline treatment in EGFR-mutant lung cancer has changed the landscape of how we treat EGFR-mutant lung cancer. In the past, we gave drugs that had a fair ...

Dec 4th, 2020 - Maura N. Dickler, MD The combination of ramucirumab (Cyramza) and erlotinib (Tarceva) significantly improved progression-free survival (PFS) compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non...

May 5th, 2020 - Extending the lifespans of patients with breast cancer with novel therapeutic interventions comes with a downside: It has made patients more susceptible to leptomeningeal carcinomatosis (LC), an increasingly prevalent secondary disease. Estimated ...